Abstract
The intra vitam diagnosis of different dementias is still based on clinical grounds. So far, no technical investigations have been available to support these diagnoses. For tau protein and β-amyloid(1–42) in cere-brospinal fluid (CSF), promising results for the diagnosis of Alzheimer's disease (AD) have been reported; however, their differential diagnostic spectrum is limited, as was recently shown for dementia with Lewy bodies (DLB) and for AD. Therefore, further marker proteins have to be established to ameliorate, support, and differentiate these clinical diagnoses. We evaluated β-amyloid(1–40) and phosphorylated tau protein (181p), in addition to total tau protein and β-amyloid(1–42), in 20 patients with DLB, 34 AD patients, and 20 non-demented neurological controls (NDCs). All markers could differentiate between the dementia groups (AD, DLB) and the controls. AD and DLB could be differentiated only by levels of total tau protein and by the ratio total tau protein/phosphorylated tau protein. However, values still overlapped markedly. In some cases, tau protein levels in CSF may contribute to the clinical distinction between DLB and AD, but the value of the markers is still limited, especially because of mixed pathology. We conclude that more specific markers have to be established to differentiate between these diseases.
References
1. McKeith IG, Galasko D, Kosaka, Perry EK, Dickson DW, Hansen L, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy-bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113–24.10.1212/WNL.47.5.1113Search in Google Scholar
2. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J Am Med Assoc 2003; 289:2094–103.10.1001/jama.289.16.2094Search in Google Scholar
3. Gomez-Tostosa E, Gonzales I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003; 60:1218–22.Search in Google Scholar
4. Tschampa H, Schulz-Schaeffer WJ, Wiltfang J, Poser S, Otto M, Neumann N, et al. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies. Neurology 2001; 56:576.10.1212/WNL.56.4.576Search in Google Scholar
5. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19:164–70.10.1159/000083178Search in Google Scholar
6. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 2005; 112:933–48.10.1007/s00702-004-0235-7Search in Google Scholar
7. Harrington CR, Perry RH, Perry EK, Hurt J, McKeith IG, Roth M, et al. Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 1994; 5:215–22.Search in Google Scholar
8. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F, et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001; 22:77–8.10.1007/s100720170055Search in Google Scholar
9. Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002; 59:1267–72.10.1001/archneur.59.8.1267Search in Google Scholar
10. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD-patients using β-amyloid(1–42) and tau levels in CSF. Neurology 1999; 52:1555–62.10.1212/WNL.52.8.1555Search in Google Scholar
11. Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau. Neurobiol Aging 2004; 25:273–81.10.1016/S0197-4580(03)00086-1Search in Google Scholar
12. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998; 44:17–26.10.1002/ana.410440108Search in Google Scholar PubMed
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939–44.10.1212/WNL.34.7.939Search in Google Scholar
14. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in differential diagnosis of Alzheimer's disease. Arch Gen Psychiatry 2004; 61:95–102.10.1001/archpsyc.61.1.95Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
